IRLAB Launches Heavily Backed Rights Issue to Fund Pipeline and Extend Runway

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has issued an announcement.

IRLAB Therapeutics plans to raise approximately SEK 68 million through a rights issue of series A shares, with an additional SEK 33.8 million available via an overallotment issue, both subject to shareholder approval and changes to the articles of association. The offering is priced at SEK 1.20 per share, about a 15 percent discount to the latest close, and is largely backed by subscription undertakings and intentions covering roughly 91 percent of the issue, while the company also extends most of its loan from Fenja Capital to late 2027, repaying a smaller portion upon completion of the rights issue.

The capital injection is intended to strengthen IRLAB’s balance sheet, support ongoing partnership negotiations aimed at securing at least one revenue-generating collaboration this year, and fund preclinical work and manufacturing for drug candidate IRL1117, as well as development of IRL757. Management says a fully subscribed rights and overallotment issue would finance the company into the fourth quarter of 2027, beyond the mid-2027 data readout for the IRL757 clinical trial, while helping reduce reliance on debt and enhancing the attractiveness of its pipeline to potential partners and investors.

More about IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB is a Swedish biopharmaceutical company focused on developing novel treatments for neurological disorders, including Parkinson’s disease and related conditions. The company advances a pipeline of drug candidates such as IRL757 and IRL1117, targeting unmet medical needs in movement and neurodegenerative diseases for a global market.

Average Trading Volume: 219,206

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK119.6M

For detailed information about IRLAB.A stock, go to TipRanks’ Stock Analysis page.